These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 36589601)

  • 1. Pregnancy outcomes between pregnant systemic lupus erythematosus patients with clinical remission and those with low disease activity: A comparative study.
    Louthrenoo W; Trongkamolthum T; Kasitanon N; Wongthanee A
    Arch Rheumatol; 2022 Sep; 37(3):361-374. PubMed ID: 36589601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes.
    Pawlak-Buś K; Schmidt W; Leszczyński P
    Eur Rev Med Pharmacol Sci; 2023 Feb; 27(3):949-959. PubMed ID: 36808341
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequencies and predictors of the Lupus Low Disease Activity State and remission in treatment-naïve patients with systemic lupus erythematosus.
    Gao D; Hao Y; Mu L; Xie W; Fan Y; Ji L; Zhang Z
    Rheumatology (Oxford); 2020 Nov; 59(11):3400-3407. PubMed ID: 32337549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission.
    Zen M; Iaccarino L; Gatto M; Saccon F; Larosa M; Ghirardello A; Punzi L; Doria A
    Ann Rheum Dis; 2018 Jan; 77(1):104-110. PubMed ID: 28970217
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study.
    Tani C; Zucchi D; Haase I; Larosa M; Crisafulli F; Strigini FAL; Monacci F; Elefante E; Mucke J; Choi MY; Andreoli L; Iaccarino L; Tincani A; Doria A; Fischer-Betz R; Mosca M
    Rheumatology (Oxford); 2021 Dec; 60(12):5610-5619. PubMed ID: 33590843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does expert opinion match the definition of lupus low disease activity state? Prospective analysis of 500 patients from a Spanish multicentre cohort.
    Altabás-González I; Rúa-Figueroa I; Rubiño F; Mouriño Rodríguez C; Hernández-Rodríguez I; Menor Almagro R; Uriarte Isacelaya E; Tomero Muriel E; Salman-Monte TC; Carrión-Barberà I; Galindo M; Rodríguez Almaraz EM; Jiménez N; Inês L; Pego-Reigosa JM
    Rheumatology (Oxford); 2023 Mar; 62(3):1162-1169. PubMed ID: 35961050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort.
    Tani C; Vagelli R; Stagnaro C; Carli L; Mosca M
    Lupus Sci Med; 2018; 5(1):e000234. PubMed ID: 29531772
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS).
    Abdelhady EI; Rabie M; Hassan RA
    Clin Rheumatol; 2021 Nov; 40(11):4553-4558. PubMed ID: 34142298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study.
    Larosa M; Le Guern V; Guettrot-Imbert G; Morel N; Abisror N; Morati-Hafsaoui C; Orquevaux P; Diot E; Doria A; Sarrot-Reynauld F; Limal N; Queyrel V; Souchaud-Debouverie O; Sailler L; Le Besnerais M; Goulenok T; Molto A; Pannier-Metzger E; Sentilhes L; Mouthon L; Lazaro E; Costedoat-Chalumeau N;
    Rheumatology (Oxford); 2022 Aug; 61(9):3657-3666. PubMed ID: 35015828
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort.
    Ugarte-Gil MF; Gamboa-Cardenas RV; Reátegui-Sokolova C; Pimentel-Quiroz VR; Medina M; Elera-Fitzcarrald C; Zevallos F; Pastor-Asurza CA; Lofland J; Zazzetti F; Karyekar CS; Alarcón GS; Perich-Campos RA
    Lupus Sci Med; 2022 Feb; 9(1):. PubMed ID: 35193948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Caveats and pitfalls in defining low disease activity in systemic lupus erythematosus.
    Samões B; Zen M; Abelha-Aleixo J; Gatto M; Doria A
    Autoimmun Rev; 2022 Oct; 21(10):103165. PubMed ID: 35931316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus.
    Kikuchi J; Hanaoka H; Saito S; Oshige T; Hiramoto K; Kaneko Y; Takeuchi T
    Rheumatology (Oxford); 2022 Aug; 61(9):3777-3791. PubMed ID: 35015824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial:
    Morand EF; Trasieva T; Berglind A; Illei GG; Tummala R
    Ann Rheum Dis; 2018 May; 77(5):706-713. PubMed ID: 29420200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low disease activity state in juvenile-onset systemic lupus erythematosus.
    Ozturk K; Caglayan S; Tanatar A; Baglan E; Yener Otar G; Kavrul Kayaalp G; Karadag SG; Demir F; Sonmez HE; Ozdel S; Cakan M; Aktay Ayaz N; Sozeri B;
    Lupus; 2021 Nov; 30(13):2144-2150. PubMed ID: 34723709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Flare rates and factors determining flare occurrence in patients with systemic lupus erythematosus who achieved low disease activity or remission: results from a prospective cohort study.
    Hao Y; Ji L; Gao D; Fan Y; Geng Y; Zhang X; Li G; Zhang Z
    Lupus Sci Med; 2022 Mar; 9(1):. PubMed ID: 35241499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Target in Newly Diagnosed Systemic Lupus Erythematosus: The Association of Lupus Low Disease Activity State and Remission With Lower Accrual of Early Damage.
    Floris A; Piga M; Perra D; Chessa E; Congia M; Mathieu A; Cauli A
    Arthritis Care Res (Hoboken); 2020 Dec; 72(12):1794-1799. PubMed ID: 31600023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Does remission in systemic lupus erythematosus according to the 2021 DORIS definition match the treating rheumatologist's judgement?
    Altabás-González I; Rúa-Figueroa Í; Rubiño F; Mouriño C; Hernández-Rodriguez Í; Menor-Almagro R; Uriarte-Isacelaya E; Tomero E; Salman-Monte TC; Carrión-Barberá I; Galindo-Izquierdo M; Rodriguez-Almaraz ME; Inês LS; Jiménez N; Pego-Reigosa JM
    Rheumatology (Oxford); 2024 Jan; 63(1):72-78. PubMed ID: 37039851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus.
    Na Nakorn K; Piyaphanee N; Sukharomana M; Pinpatanapong R; Charuvanij S
    Clin Rheumatol; 2023 Jun; 42(6):1655-1664. PubMed ID: 36780064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience.
    Tani C; Elefante E; Signorini V; Zucchi D; Lorenzoni V; Carli L; Stagnaro C; Ferro F; Mosca M
    RMD Open; 2019; 5(2):e000916. PubMed ID: 31275608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS).
    Franklyn K; Lau CS; Navarra SV; Louthrenoo W; Lateef A; Hamijoyo L; Wahono CS; Chen SL; Jin O; Morton S; Hoi A; Huq M; Nikpour M; Morand EF;
    Ann Rheum Dis; 2016 Sep; 75(9):1615-21. PubMed ID: 26458737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.